|Articles|June 1, 2002
Latanoprost plus brimonidine controls IOP
Austin, TX-Patients who need more than one ocular hypotensive agent to achieve low IOP may benefit more from a regimen of latanoprost (Xalatan, Pharmacia) and adjunctive brimonidine (Alphagan, Allergan) than from dual therapy with latanoprost and timolol, according to a recent study.
Advertisement
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Eye Care Network - Ophthalmology Times
1
FAQ: What retina specialists need to know about the MOGENRY (MCO-010) BLA acceptance
2
RCA releases first State of Retina Care report
3
OT Roundup ep. 1: ADHD's eye link, MOGENRY's BLA, and myopia news
4
Linsitinib phase 3 ORBIT trial doses first patients for thyroid eye disease
5






